ReP USP - Resultado da busca

Artigo de periodico
Liquid crystalline nanoparticles enable a multifunctional approach for topical psoriasis therapy by co-delivering triptolide and siRNAs (2023)
Silvestrini, Ana Vitória Pupo ; Praça, Fabíola Garcia; Leite, Marcel Nani; Fantini, Marcia ; Frade, Marco Andrey Cipriani ; Bentley, M. V. L. B.
Fonte: International Journal of Pharmaceutics. Unidades: FCFRP, IF, FMRP
Assuntos: BIOFÍSICA, MATERIAIS NANOESTRUTURADOS, ESPALHAMENTO DE RAIOS X A BAIXOS ÂNGULOS, CRISTAIS LÍQUIDOS, FARMACOLOGIA, PSORÍASE, GENÉTICA BIOQUÍMICA, RNA, TRIPTERYGIIDAE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVESTRINI, Ana Vitória Pupo et al. Liquid crystalline nanoparticles enable a multifunctional approach for topical psoriasis therapy by co-delivering triptolide and siRNAs. International Journal of Pharmaceutics, v. 640, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.ijpharm.2023.123019. Acesso em: 13 nov. 2024.
APA
Silvestrini, A. V. P., Praça, F. G., Leite, M. N., Fantini, M., Frade, M. A. C., & Bentley, M. V. L. B. (2023). Liquid crystalline nanoparticles enable a multifunctional approach for topical psoriasis therapy by co-delivering triptolide and siRNAs. International Journal of Pharmaceutics, 640. doi:10.1016/j.ijpharm.2023.123019
NLM
Silvestrini AVP, Praça FG, Leite MN, Fantini M, Frade MAC, Bentley MVLB. Liquid crystalline nanoparticles enable a multifunctional approach for topical psoriasis therapy by co-delivering triptolide and siRNAs [Internet]. International Journal of Pharmaceutics. 2023 ; 640[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.ijpharm.2023.123019
Vancouver
Silvestrini AVP, Praça FG, Leite MN, Fantini M, Frade MAC, Bentley MVLB. Liquid crystalline nanoparticles enable a multifunctional approach for topical psoriasis therapy by co-delivering triptolide and siRNAs [Internet]. International Journal of Pharmaceutics. 2023 ; 640[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.ijpharm.2023.123019
Artigo de periodico
How do sphingolipids play a role in epigenetic mechanisms and gene expression? (2022)
Silva, Gabriel da ; Coeli-Lacchini, Fernanda Borchers; Leopoldino, Andréia Machado
Fonte: Epigenomics. Unidades: FMRP, FCFRP
Assuntos: METILAÇÃO DE DNA, EPIGÊNESE GENÉTICA, EXPRESSÃO GÊNICA, LIPÍDEOS DA MEMBRANA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Gabriel da e COELI-LACCHINI, Fernanda Borchers e LEOPOLDINO, Andréia Machado. How do sphingolipids play a role in epigenetic mechanisms and gene expression?. Epigenomics, v. 14, n. 5, p. 219-222, 2022Tradução . . Disponível em: https://doi.org/10.2217/epi-2021-0425. Acesso em: 13 nov. 2024.
APA
Silva, G. da, Coeli-Lacchini, F. B., & Leopoldino, A. M. (2022). How do sphingolipids play a role in epigenetic mechanisms and gene expression? Epigenomics, 14( 5), 219-222. doi:10.2217/epi-2021-0425
NLM
Silva G da, Coeli-Lacchini FB, Leopoldino AM. How do sphingolipids play a role in epigenetic mechanisms and gene expression? [Internet]. Epigenomics. 2022 ; 14( 5): 219-222.[citado 2024 nov. 13 ] Available from: https://doi.org/10.2217/epi-2021-0425
Vancouver
Silva G da, Coeli-Lacchini FB, Leopoldino AM. How do sphingolipids play a role in epigenetic mechanisms and gene expression? [Internet]. Epigenomics. 2022 ; 14( 5): 219-222.[citado 2024 nov. 13 ] Available from: https://doi.org/10.2217/epi-2021-0425
Artigo de periodico
Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics (2022)
Pavan, Marcella; Yamamoto, Priscila; Silva, Rodrigo Moreira da; Salgado Junior, Wilson; Santos, José dos; Kemp, Rafael; Sankarankutty, Ajith Kumar ; Moraes, Natália de; Gaitani, Cristiane de
Fonte: Journal of Chromatography B. Unidades: FCFRP, FMRP
Assuntos: QUIMIOMETRIA, CROMATOGRAFIA LÍQUIDA, ESPECTROMETRIA DE MASSAS, REPRODUTIBILIDADE DE RESULTADOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PAVAN, Marcella et al. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics. Journal of Chromatography B, v. 1205, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2022.123338. Acesso em: 13 nov. 2024.
APA
Pavan, M., Yamamoto, P., Silva, R. M. da, Salgado Junior, W., Santos, J. dos, Kemp, R., et al. (2022). Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics. Journal of Chromatography B, 1205. doi:10.1016/j.jchromb.2022.123338
NLM
Pavan M, Yamamoto P, Silva RM da, Salgado Junior W, Santos J dos, Kemp R, Sankarankutty AK, Moraes N de, Gaitani C de. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics [Internet]. Journal of Chromatography B. 2022 ; 1205[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.jchromb.2022.123338
Vancouver
Pavan M, Yamamoto P, Silva RM da, Salgado Junior W, Santos J dos, Kemp R, Sankarankutty AK, Moraes N de, Gaitani C de. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics [Internet]. Journal of Chromatography B. 2022 ; 1205[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.jchromb.2022.123338
Artigo de periodico
Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms (2022)
Cacemiro, Maira da Costa ; Cominal, Juçara Gastaldi ; Pereira, Luiz Miguel ; Berzoti-Coelho, Maria Gabriela ; Berbel, Giovana Michelassi; Baroni, Luciana ; Pereira, Tathiane Maistro Malta ; Tognon, Raquel; Nunes, Natália de Souza ; Souto, Elizabeth Xisto; Pontes, Lorena Lobo de Figueiredo ; Natsui, Ana Patrícia Yatsuda ; Castro, Fabíola Attié de
Fonte: Medical Oncology. Unidades: FCFRP, FMRP, ESALQ, FFCLRP, IQ
Assuntos: APOPTOSE, EXPRESSÃO GÊNICA, HIPOTÁLAMO, NEOPLASIAS, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CACEMIRO, Maira da Costa et al. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical Oncology, v. 39, n. 5, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12032-022-01696-x. Acesso em: 13 nov. 2024.
APA
Cacemiro, M. da C., Cominal, J. G., Pereira, L. M., Berzoti-Coelho, M. G., Berbel, G. M., Baroni, L., et al. (2022). Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical Oncology, 39( 5), 1-11. doi:10.1007/s12032-022-01696-x
NLM
Cacemiro M da C, Cominal JG, Pereira LM, Berzoti-Coelho MG, Berbel GM, Baroni L, Pereira TMM, Tognon R, Nunes N de S, Souto EX, Pontes LL de F, Natsui APY, Castro FA de. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms [Internet]. Medical Oncology. 2022 ; 39( 5): 1-11.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s12032-022-01696-x
Vancouver
Cacemiro M da C, Cominal JG, Pereira LM, Berzoti-Coelho MG, Berbel GM, Baroni L, Pereira TMM, Tognon R, Nunes N de S, Souto EX, Pontes LL de F, Natsui APY, Castro FA de. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms [Internet]. Medical Oncology. 2022 ; 39( 5): 1-11.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s12032-022-01696-x
Artigo de periodico
Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model (2021)
Pinto, Leonardo Santos Ribeiro; Bapat, Priya; Moreira, Fernanda de Lima; Lubetsky, Angelika; Cavalli, Ricardo de Carvalho; Berger, Howard; Lanchote, Vera Lucia ; Koren, Gideon
Fonte: Pharmaceutical Research. Unidades: FCFRP, FMRP
Assuntos: ANTAGONISTAS, FARMACOTERAPIA, ANTIDEPRESSIVOS, PLACENTA, COMPLICAÇÕES NA GRAVIDEZ, ANTI-HISTAMÍNICOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, v. 38, n. 4, p. 647-655, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11095-021-03035-7. Acesso em: 13 nov. 2024.
APA
Pinto, L. S. R., Bapat, P., Moreira, F. de L., Lubetsky, A., Cavalli, R. de C., Berger, H., et al. (2021). Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, 38( 4), 647-655. doi:10.1007/s11095-021-03035-7
NLM
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Vancouver
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Artigo de periodico
Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (2021)
Cominal, Juçara Gastaldi; Cacemiro, Maira da Costa ; Berzoti-Coelho, Maria Gabriela ; Pereira, Illy Enne Gomes ; Frantz, Fabiani Gai ; Souto, Elizabeth Xisto; Covas, Dimas Tadeu; Figueiredo-Pontes, Lorena Lobo de; Oliveira, Maria Carolina; Malmegrim, Kelen Cristina Ribeiro ; Castro, Fabíola Attié de
Fonte: Frontiers in Oncology. Unidades: FCFRP, FMRP
Assuntos: NEOVASCULARIZAÇÃO PATOLÓGICA, MEDULA ÓSSEA, CITOCINAS, INFLAMAÇÃO, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COMINAL, Juçara Gastaldi et al. Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Frontiers in Oncology, v. 11, p. 1-12 , 2021Tradução . . Disponível em: https://doi.org/10.3389/fonc.2021.665037. Acesso em: 13 nov. 2024.
APA
Cominal, J. G., Cacemiro, M. da C., Berzoti-Coelho, M. G., Pereira, I. E. G., Frantz, F. G., Souto, E. X., et al. (2021). Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Frontiers in Oncology, 11, 1-12 . doi:10.3389/fonc.2021.665037
NLM
Cominal JG, Cacemiro M da C, Berzoti-Coelho MG, Pereira IEG, Frantz FG, Souto EX, Covas DT, Figueiredo-Pontes LL de, Oliveira MC, Malmegrim KCR, Castro FA de. Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms [Internet]. Frontiers in Oncology. 2021 ; 11 1-12 .[citado 2024 nov. 13 ] Available from: https://doi.org/10.3389/fonc.2021.665037
Vancouver
Cominal JG, Cacemiro M da C, Berzoti-Coelho MG, Pereira IEG, Frantz FG, Souto EX, Covas DT, Figueiredo-Pontes LL de, Oliveira MC, Malmegrim KCR, Castro FA de. Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms [Internet]. Frontiers in Oncology. 2021 ; 11 1-12 .[citado 2024 nov. 13 ] Available from: https://doi.org/10.3389/fonc.2021.665037
Artigo de periodico
Ex vivo model of human skin (hOSEC) for assessing the dermatokinetics of the anti-melanoma drug dacarbazine (2021)
Leite, Marcel Nani; Viegas, Juliana Santos Rosa ; Praça, Fabíola ; Paula, Natália Aparecida de ; Ramalho, Leandra Naíra Zambelli; Bentley, Maria Vitória Lopes Badra ; Frade, Marco Andrey Cipriani
Fonte: European Journal of Pharmaceutical Sciences. Unidades: FCFRP, FMRP
Assuntos: FÁRMACOS, PELE, ANTINEOPLÁSICOS, FIBROBLASTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEITE, Marcel Nani et al. Ex vivo model of human skin (hOSEC) for assessing the dermatokinetics of the anti-melanoma drug dacarbazine. European Journal of Pharmaceutical Sciences, v. 160, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2021.105769. Acesso em: 13 nov. 2024.
APA
Leite, M. N., Viegas, J. S. R., Praça, F., Paula, N. A. de, Ramalho, L. N. Z., Bentley, M. V. L. B., & Frade, M. A. C. (2021). Ex vivo model of human skin (hOSEC) for assessing the dermatokinetics of the anti-melanoma drug dacarbazine. European Journal of Pharmaceutical Sciences, 160. doi:10.1016/j.ejps.2021.105769
NLM
Leite MN, Viegas JSR, Praça F, Paula NA de, Ramalho LNZ, Bentley MVLB, Frade MAC. Ex vivo model of human skin (hOSEC) for assessing the dermatokinetics of the anti-melanoma drug dacarbazine [Internet]. European Journal of Pharmaceutical Sciences. 2021 ; 160[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.ejps.2021.105769
Vancouver
Leite MN, Viegas JSR, Praça F, Paula NA de, Ramalho LNZ, Bentley MVLB, Frade MAC. Ex vivo model of human skin (hOSEC) for assessing the dermatokinetics of the anti-melanoma drug dacarbazine [Internet]. European Journal of Pharmaceutical Sciences. 2021 ; 160[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.ejps.2021.105769
Artigo de periodico
Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
Tozatto, Eduardo; Benzi, Jhohann Richard de Lima ; Rocha, Adriana; Coelho, Eduardo Barbosa ; Lanchote, Vera Lucia
Fonte: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Assuntos: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 13 nov. 2024.
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1002/jcph.1745
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1002/jcph.1745
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Fonte: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Assuntos: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 13 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study (2020)
Pinto, Leonardo Santos Ribeiro; Vale, Gabriel Tavares do ; Moreira, Fernanda de Lima ; Pereira, Maria Paula Marques ; Coelho, Eduardo Barbosa ; Cavalli, Ricardo de Carvalho ; Lanchote, Vera Lucia
Fonte: Journal of Chromatography B. Unidades: FCFRP, FMRP, EERP
Assuntos: ANTI-HISTAMÍNICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, PLASMA, GRAVIDEZ, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, v. 1145, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122094. Acesso em: 13 nov. 2024.
APA
Pinto, L. S. R., Vale, G. T. do, Moreira, F. de L., Pereira, M. P. M., Coelho, E. B., Cavalli, R. de C., & Lanchote, V. L. (2020). Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, 1145. doi:10.1016/j.jchromb.2020.122094
NLM
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Vancouver
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Artigo de periodico
Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2 (2020)
Clososki, Giuliano Cesar ; Soldi, Rafael A.; Silva, Rodrigo Moreira da ; Guaratini, Thais; Lopes, Jose Norberto Callegari; Pereira, Pâmela Rodrigues Rosa; Lopes, João Luis Callegari ; Santos, Thiago dos ; Martins Júnior, Ronaldo Bragança; Costa, Cristina Santos da; Carvalho, Andreia Nogueira de ; Silva, Luis Lamberti Pinto da ; Arruda, Eurico ; Lopes, Norberto Peporine
Fonte: Journal of the Brazilian Chemical Society. Unidades: FCFRP, FMRP
Assuntos: METABÓLITOS, COVID-19, ESPECTROSCOPIA INFRAVERMELHA, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CLOSOSKI, Giuliano Cesar et al. Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. Journal of the Brazilian Chemical Society, v. 31, n. 8, p. 1552-1556, 2020Tradução . . Disponível em: https://doi.org/10.21577/0103-5053.20200106. Acesso em: 13 nov. 2024.
APA
Clososki, G. C., Soldi, R. A., Silva, R. M. da, Guaratini, T., Lopes, J. N. C., Pereira, P. R. R., et al. (2020). Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. Journal of the Brazilian Chemical Society, 31( 8), 1552-1556. doi:10.21577/0103-5053.20200106
NLM
Clososki GC, Soldi RA, Silva RM da, Guaratini T, Lopes JNC, Pereira PRR, Lopes JLC, Santos T dos, Martins Júnior RB, Costa CS da, Carvalho AN de, Silva LLP da, Arruda E, Lopes NP. Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2 [Internet]. Journal of the Brazilian Chemical Society. 2020 ; 31( 8): 1552-1556.[citado 2024 nov. 13 ] Available from: https://doi.org/10.21577/0103-5053.20200106
Vancouver
Clososki GC, Soldi RA, Silva RM da, Guaratini T, Lopes JNC, Pereira PRR, Lopes JLC, Santos T dos, Martins Júnior RB, Costa CS da, Carvalho AN de, Silva LLP da, Arruda E, Lopes NP. Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2 [Internet]. Journal of the Brazilian Chemical Society. 2020 ; 31( 8): 1552-1556.[citado 2024 nov. 13 ] Available from: https://doi.org/10.21577/0103-5053.20200106
Artigo de periodico
A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women (2020)
Benzi, Jhohann Richard de Lima ; Moreira, Fernanda de Lima; Marques, Maria Paula ; Duarte, Geraldo; Suarez-Kurtz, Guilherme; Lanchote, Vera Lucia
Fonte: Journal of Chromatography B. Unidades: FCFRP, FMRP
Assuntos: LÍQUIDOS CORPORAIS, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, CITOCROMO P-450, INFECÇÕES POR HIV, CORTISOL, ESPECTROMETRIA DE MASSAS, FENÓTIPOS, GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENZI, Jhohann Richard de Lima et al. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. Journal of Chromatography B, v. 1144 , 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122074. Acesso em: 13 nov. 2024.
APA
Benzi, J. R. de L., Moreira, F. de L., Marques, M. P., Duarte, G., Suarez-Kurtz, G., & Lanchote, V. L. (2020). A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. Journal of Chromatography B, 1144 . doi:10.1016/j.jchromb.2020.122074
NLM
Benzi JR de L, Moreira F de L, Marques MP, Duarte G, Suarez-Kurtz G, Lanchote VL. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women [Internet]. Journal of Chromatography B. 2020 ; 1144 [citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122074
Vancouver
Benzi JR de L, Moreira F de L, Marques MP, Duarte G, Suarez-Kurtz G, Lanchote VL. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women [Internet]. Journal of Chromatography B. 2020 ; 1144 [citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122074
Artigo de periodico
One-week high-intensity interval training increases hippocampal plasticity and mitochondrial content without changes in redox state (2020)
Santos, Jonathas Rodrigo dos; Bortolanza, Mariza; Ferrari, Gustavo Duarte ; Lanfredi, Guilherme Pauperio ; Nascimento, Glauce Crivelaro do ; Azzolini, Ana Elisa Caleiro Seixas ; Del Bel, Elaine Aparecida ; Campos, Alline Cristina de; Faça, Vitor Marcel ; Vulczak, Anderson; Alberici, Luciane Carla
Fonte: Antioxidants. Unidades: FMRP, FORP, FCFRP
Assuntos: EXERCÍCIO FÍSICO, ESTRESSE OXIDATIVO, NEUROGENÉTICA, CÉREBRO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Jonathas Rodrigo dos et al. One-week high-intensity interval training increases hippocampal plasticity and mitochondrial content without changes in redox state. Antioxidants, v. 9, n. 5, 2020Tradução . . Disponível em: https://doi.org/10.3390/antiox9050445. Acesso em: 13 nov. 2024.
APA
Santos, J. R. dos, Bortolanza, M., Ferrari, G. D., Lanfredi, G. P., Nascimento, G. C. do, Azzolini, A. E. C. S., et al. (2020). One-week high-intensity interval training increases hippocampal plasticity and mitochondrial content without changes in redox state. Antioxidants, 9( 5). doi:10.3390/antiox9050445
NLM
Santos JR dos, Bortolanza M, Ferrari GD, Lanfredi GP, Nascimento GC do, Azzolini AECS, Del Bel EA, Campos AC de, Faça VM, Vulczak A, Alberici LC. One-week high-intensity interval training increases hippocampal plasticity and mitochondrial content without changes in redox state [Internet]. Antioxidants. 2020 ; 9( 5):[citado 2024 nov. 13 ] Available from: https://doi.org/10.3390/antiox9050445
Vancouver
Santos JR dos, Bortolanza M, Ferrari GD, Lanfredi GP, Nascimento GC do, Azzolini AECS, Del Bel EA, Campos AC de, Faça VM, Vulczak A, Alberici LC. One-week high-intensity interval training increases hippocampal plasticity and mitochondrial content without changes in redox state [Internet]. Antioxidants. 2020 ; 9( 5):[citado 2024 nov. 13 ] Available from: https://doi.org/10.3390/antiox9050445
Artigo de periodico
Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics (2020)
Pinto, Leonardo Santos Ribeiro; Moreira, Fernanda de Lima ; Nardotto, Glauco Henrique Balthazar ; Cavalli, Ricardo de Carvalho ; Moisés, Elaine Christine Dantas ; Duarte, Geraldo ; Lanchote, Vera Lucia
Fonte: Pharmaceutical Research. Unidades: FCFRP, FMRP
Assuntos: ANTIDEPRESSIVOS, FARMACOCINÉTICA, GRAVIDEZ, ESTUDOS DE CASOS E CONTROLES, MUCOSA INTESTINAL, ANTI-HISTAMÍNICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, v. 37, n. 7, 2020Tradução . . Disponível em: https://doi.org/10.1007/s11095-020-02854-4. Acesso em: 13 nov. 2024.
APA
Pinto, L. S. R., Moreira, F. de L., Nardotto, G. H. B., Cavalli, R. de C., Moisés, E. C. D., Duarte, G., & Lanchote, V. L. (2020). Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, 37( 7). doi:10.1007/s11095-020-02854-4
NLM
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Vancouver
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Artigo de periodico
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis (2020)
Viegas, Juliana Santos Rosa ; Praça, Fabíola Silva Garcia ; Caron, Angelo Luis ; Suzuki, Isabella Luiz ; Silvestrini, Ana Vitória Pupo ; Medina, Wanessa Silva Garcia; Del Ciampo, Luiz Antonio ; Kravicz, Marcelo Henrique; Bentley, Maria Vitória Lopes Badra
Fonte: Drug Delivery and Translational Research. Unidades: FCFRP, FMRP
Assuntos: NANOPARTÍCULAS, PSORÍASE, MEDICAMENTO TÓPICO, CITOCINAS, GENÉTICA, FÁRMACOS IMUNOSSUPRESSORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEGAS, Juliana Santos Rosa et al. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Delivery and Translational Research, v. 10, n. 3, p. 646-660, 2020Tradução . . Disponível em: https://doi.org/10.1007/s13346-020-00723-6. Acesso em: 13 nov. 2024.
APA
Viegas, J. S. R., Praça, F. S. G., Caron, A. L., Suzuki, I. L., Silvestrini, A. V. P., Medina, W. S. G., et al. (2020). Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Delivery and Translational Research, 10( 3), 646-660. doi:10.1007/s13346-020-00723-6
NLM
Viegas JSR, Praça FSG, Caron AL, Suzuki IL, Silvestrini AVP, Medina WSG, Del Ciampo LA, Kravicz MH, Bentley MVLB. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis [Internet]. Drug Delivery and Translational Research. 2020 ; 10( 3): 646-660.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s13346-020-00723-6
Vancouver
Viegas JSR, Praça FSG, Caron AL, Suzuki IL, Silvestrini AVP, Medina WSG, Del Ciampo LA, Kravicz MH, Bentley MVLB. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis [Internet]. Drug Delivery and Translational Research. 2020 ; 10( 3): 646-660.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s13346-020-00723-6
Artigo de periodico
NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation (2020)
Castro, Ricardo Cardoso ; Zambuzi, Fabiana Albani ; Fontanari, Caroline ; Morais, Fabiana Rossetto de; Bollela, Valdes Roberto ; Kunkel, Steven L.; Schaller, Matthew A.; Frantz, Fabiani Gai
Fonte: Tuberculosis. Unidades: FCFRP, FMRP
Assuntos: SISTEMA IMUNE, MYCOBACTERIUM TUBERCULOSIS, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO, Ricardo Cardoso et al. NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation. Tuberculosis, v. 124, p. 1-10, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.tube.2020.101980. Acesso em: 13 nov. 2024.
APA
Castro, R. C., Zambuzi, F. A., Fontanari, C., Morais, F. R. de, Bollela, V. R., Kunkel, S. L., et al. (2020). NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation. Tuberculosis, 124, 1-10. doi:10.1016/j.tube.2020.101980
NLM
Castro RC, Zambuzi FA, Fontanari C, Morais FR de, Bollela VR, Kunkel SL, Schaller MA, Frantz FG. NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation [Internet]. Tuberculosis. 2020 ; 124 1-10.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.tube.2020.101980
Vancouver
Castro RC, Zambuzi FA, Fontanari C, Morais FR de, Bollela VR, Kunkel SL, Schaller MA, Frantz FG. NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation [Internet]. Tuberculosis. 2020 ; 124 1-10.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.tube.2020.101980
Artigo de periodico
Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats (2019)
Porto, Hellen Karine Paes; Grando, Marcella Daruge; Ramalho, Leandra Naira Zambelli ; Valadares, Marize Campos ; Bendhack, Lusiane Maria ; Batista, Aline Carvalho ; Rocha, Matheus Lavorenti
Fonte: Archives of Toxicology. Unidades: FCFRP, FMRP
Assuntos: SISTEMA CARDIOVASCULAR, PARACETAMOL, ESTRESSE OXIDATIVO, VASODILATAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PORTO, Hellen Karine Paes et al. Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats. Archives of Toxicology, v. 93, n. 7, p. 1955-1964, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00204-019-02463-0. Acesso em: 13 nov. 2024.
APA
Porto, H. K. P., Grando, M. D., Ramalho, L. N. Z., Valadares, M. C., Bendhack, L. M., Batista, A. C., & Rocha, M. L. (2019). Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats. Archives of Toxicology, 93( 7), 1955-1964. doi:10.1007/s00204-019-02463-0
NLM
Porto HKP, Grando MD, Ramalho LNZ, Valadares MC, Bendhack LM, Batista AC, Rocha ML. Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats [Internet]. Archives of Toxicology. 2019 ; 93( 7): 1955-1964.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s00204-019-02463-0
Vancouver
Porto HKP, Grando MD, Ramalho LNZ, Valadares MC, Bendhack LM, Batista AC, Rocha ML. Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats [Internet]. Archives of Toxicology. 2019 ; 93( 7): 1955-1964.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1007/s00204-019-02463-0
Artigo de periodico
Activation of TP receptors induces high release of PGI2 in coronary arteries of renal hypertensive rats (2018)
Paula, Tiago Dal-Cin de; Silva, Bruno Rodrigues da; Grando, Marcella Daruge; Souza, Hugo Celso Dutra de; Bendhack, Lusiane Maria
Fonte: Journal of Molecular and Cellular Cardiology. Unidades: FCFRP, FMRP
Assuntos: HIPERTENSÃO, VASOS CORONÁRIOS, RATOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PAULA, Tiago Dal-Cin de et al. Activation of TP receptors induces high release of PGI2 in coronary arteries of renal hypertensive rats. Journal of Molecular and Cellular Cardiology, v. 122, p. 125-133, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.yjmcc.2018.08.007. Acesso em: 13 nov. 2024.
APA
Paula, T. D. -C. de, Silva, B. R. da, Grando, M. D., Souza, H. C. D. de, & Bendhack, L. M. (2018). Activation of TP receptors induces high release of PGI2 in coronary arteries of renal hypertensive rats. Journal of Molecular and Cellular Cardiology, 122, 125-133. doi:10.1016/j.yjmcc.2018.08.007
NLM
Paula TD-C de, Silva BR da, Grando MD, Souza HCD de, Bendhack LM. Activation of TP receptors induces high release of PGI2 in coronary arteries of renal hypertensive rats [Internet]. Journal of Molecular and Cellular Cardiology. 2018 ; 122 125-133.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.yjmcc.2018.08.007
Vancouver
Paula TD-C de, Silva BR da, Grando MD, Souza HCD de, Bendhack LM. Activation of TP receptors induces high release of PGI2 in coronary arteries of renal hypertensive rats [Internet]. Journal of Molecular and Cellular Cardiology. 2018 ; 122 125-133.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.yjmcc.2018.08.007
Artigo de periodico
A soluble recombinant form of human leucocyte antigen-G 6 (srHLA-G6) (2017)
Pelá, Flávia Porto; Rustiguel, Joane Kathelen; Rodrigues, Lilian Cataldi; Mendonça, Jacqueline Nakau; Andrade, Camillo Del Cistia; Lopes, Norberto Peporine; Rosa, José Cesar; Nonato, Maria Cristina; Favier, Benoit; Donadi, Eduardo Antônio; Dias-Baruffi, Marcelo
Fonte: Biochemical and Biophysical Research Communications. Unidades: FCFRP, FMRP
Assuntos: ANTÍGENOS, LEUCÓCITOS, PROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PELÁ, Flávia Porto et al. A soluble recombinant form of human leucocyte antigen-G 6 (srHLA-G6). Biochemical and Biophysical Research Communications, v. 487, n. 1, p. 28-33, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.bbrc.2017.03.149. Acesso em: 13 nov. 2024.
APA
Pelá, F. P., Rustiguel, J. K., Rodrigues, L. C., Mendonça, J. N., Andrade, C. D. C., Lopes, N. P., et al. (2017). A soluble recombinant form of human leucocyte antigen-G 6 (srHLA-G6). Biochemical and Biophysical Research Communications, 487( 1), 28-33. doi:10.1016/j.bbrc.2017.03.149
NLM
Pelá FP, Rustiguel JK, Rodrigues LC, Mendonça JN, Andrade CDC, Lopes NP, Rosa JC, Nonato MC, Favier B, Donadi EA, Dias-Baruffi M. A soluble recombinant form of human leucocyte antigen-G 6 (srHLA-G6) [Internet]. Biochemical and Biophysical Research Communications. 2017 ; 487( 1): 28-33.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.bbrc.2017.03.149
Vancouver
Pelá FP, Rustiguel JK, Rodrigues LC, Mendonça JN, Andrade CDC, Lopes NP, Rosa JC, Nonato MC, Favier B, Donadi EA, Dias-Baruffi M. A soluble recombinant form of human leucocyte antigen-G 6 (srHLA-G6) [Internet]. Biochemical and Biophysical Research Communications. 2017 ; 487( 1): 28-33.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1016/j.bbrc.2017.03.149
Artigo de periodico
Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac (2017)
Silva, Carolina de Miranda; Rocha, Adriana; Tozatto, Eduardo; Silva, Lucienir Maria da; Donadi, Eduardo Antônio; Costa, Teresa Dalla; Lanchote, Vera Lúcia; Schmidt, Stephan; Bulitta, Jürgen B.
Fonte: The AAPS Journal. Unidades: FCFRP, FMRP
Assuntos: FARMACODINÂMICA, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Carolina de Miranda et al. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac. The AAPS Journal, v. 19, n. 6, p. 1814-1825, 2017Tradução . . Disponível em: https://doi.org/10.1208/s12248-017-0138-9. Acesso em: 13 nov. 2024.
APA
Silva, C. de M., Rocha, A., Tozatto, E., Silva, L. M. da, Donadi, E. A., Costa, T. D., et al. (2017). Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac. The AAPS Journal, 19( 6), 1814-1825. doi:10.1208/s12248-017-0138-9
NLM
Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Costa TD, Lanchote VL, Schmidt S, Bulitta JB. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac [Internet]. The AAPS Journal. 2017 ; 19( 6): 1814-1825.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1208/s12248-017-0138-9
Vancouver
Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Costa TD, Lanchote VL, Schmidt S, Bulitta JB. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac [Internet]. The AAPS Journal. 2017 ; 19( 6): 1814-1825.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1208/s12248-017-0138-9

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

País de publicação

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos